A Phase I/II Study of cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in combination with FOLFOX

Study identifier:D8480C00039

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Two Part Study in Japanese Patients with mCRC, Consisting of an Open-label Phase I Part to assess the Safety and Tolerability of cediranib (AZD2171) in combination with FOLFOX followed by a Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of cediranib (AZD2171) in combination with FOLFOX

Medical condition

Metastatic Colorectal Cancer

Phase

Phase 1/2

Healthy volunteers

No

Study drug

AZD2171, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), Placebo Cediranib

Sex

All

Actual Enrollment

172

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Jun 2007
Primary Completion Date: 01 Oct 2009
Estimated Study Completion Date: 01 Dec 2012

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 May 2012 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria